Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (The CURVES study)

American Journal of Cardiology

Volumn 81, Issue 5, 1998, Pages 582-587

  Jones, Peter ^a   Kafonek, Stephanie ^b   Laurora, Irene ^b   Hunninghake, Donald ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FLATULENCE; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; FATTY ACIDS, MONOUNSATURATED; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INDOLES; LOVASTATIN; MALE; MIDDLE AGED; PRAVASTATIN; PYRROLES; SIMVASTATIN; TREATMENT OUTCOME;

EID: 0032032592     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00965-X     Document Type: Article

References (27)

1. Expect Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-3023.
2. Jones PH, Farmer JA, Cressman MD, McKenney JM, Wright JT, Proctor JD, Berkson DM, Farnham DJ, Wolfson PM, Golfer HT, Rackley CE, Sigmund WR, Schlant RC, Arenberg D, McGovern ME. Once-daily pravastatin in patients with primary hypercholesterolemia: a dose response study. Clin Cardiol 1991;14:146-151.
3. Illingworth DR, HMG CoA reducatase inhibitors. Curr Opin Lipidol 1991;2: 24-30.
4. Illingworth DR, Tobert JA. A review of clinical trials comparing HMG CoA reductase inhibitors. Clin Ther 1994;16:366-385.
5. Weir MR, Berger ML, Weeks ML, Liss CL, Santanello NC, for the Quality of Life Multicenter Group. Comparison of the effects on quality of life and the efficacy and tolerability of lovastatin versus pravastatin. Am J Cardiol 1996;77: 475-479.
6. The Simvastatin Pravastatin Study Group. Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia. Am J Cardiol 1993;71:1408-1414.
7. Simvastatin Pravastatin European Study Group. Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia. Cardiology 1994;85:244-254.
8. Douste-Blazy P, Ribeiro VG, Seed M, and the European Study Group. Comparative study of the efficacy and tolerability of simvastatin and pravastatin in patients with primary hypercholesterolemia. Drug Invest 1993;6:353-361.
9. Illingworth DR, Stein EA, Knopp RH, Hunnighake DB, Davidson MH, Dujovne CA, Miller VT, Tobert JA, Laskarzewski PM, Isaacsohn JL, Bacon SP, Tate AC. A randomized multicenter trial comparing the efficacy of simvastatin and fluvastatin. J Cardiovasc Pharmacol Ther 1996;1:23-30.
10. Berger ML, Wilson HM, Liss CL. A comparison of the tolerability and efficacy of lovastatin 20 mg and fluvastatin 20 mg in the treatment of primary hypercholesterolemia. J Cardiovasc Pharmacol Therapeut 1996;1:101-106.
11. Jacotot B, Benghozi R, Pfister P, Holmes D, on behalf of the french fluvastatin study group. Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. Am J Cardiol 1995;76:54A-56A.
12. Schulte K, Beil S. Efficacy and tolerability of fluvastatin and simvastatin in hypercholesterolemic patients. Clin Drug Invest 1996;12:119-126.
13. Lintott CJ, Sutherland WHF, Scott RS, Bremer J. Treating hypercholesterolemia with HMG CoA reductase inhibitors: a direct comparison of simvastatin and pravastatin. Aust N Z J Med 1993;23:381-386.
14. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, Jones PH, Haber HE, Black DM. Reduction of LDL-cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vase Biol 1995;15:678-682.
15. th Congress of the European Artherosclerosis Society, July 1996:212.
16. Davidson M, McKinney J, Stein E, Schrott H, Bakker-Arkema R, Fayyad R, Black D, for the Atorvastatin Study Group I. Comparison of the one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Am J Cardiol 1997;79:1475.
17. Bertolini S, Bittolo Bon G, Cambell LM, Farnier M, Langan J, Mahla G, Pauciullo P, Sirtori C, Egros F, Fayyad R, Nawrocki JW. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis 1997;130:191-197.
18. Dart A, Jerums G, Nicholson G, d'Emden M, Hamilton-Craig I, Tallis G, Best J, West M, Sullivan D, Bracs P, Black D. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Cardiol 1997;80:39-44.
19. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499-502.
20. Myers GL, Copper GR, Winn CL, Smith SJ. The Centers for Disease Control-National Heart, Lung, and Blood Institute Lipid Standardization Program: an approach to accurate and precise lipid measurements. Clin Lab Med 1989;9:105-135.
21. Steiner PM, Freidel J, Bremmer WF, Stein EA. Standardization of micromethods for plasma cholesterol, triglyceride and HDL-cholesterol with the Lipid Research Clinics' methodology (abstr). J Clin Chem Clin Biochem 1981;19:850.
22. Steele WB, Koehle DF, Azar MM, Blaszkowski TP, Kuba K, Dempsey ME. Enzymatic determinations of cholesterol in high density lipoprotein fractions prepared by a precipitation technique. Clin Chem 1976;22:98-101.
23. Dunnett CW. A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc 1955;50:1096-1121.
24. Blum C. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol 1994;73:3D-11D.
25. Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin FA, Gould AL, Hesney M, Higgins J, Hurley DP, Langendorfer A, Nash DT, Pool JL, Schnaper H. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse events profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991;151:43-49.
26. Hsu I, Spinler SA, Johnson NE. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother 1995;29:743-759.
27. Dujovne CA, Chremos N, Pool JL, Schnaper H, Bradfrd RH, Shear CL, Higgins J, Downton M, Franklin FA, Nash DT, Gould L, Langendorfer A. Expanded Clinical Evaluation of Lovastatin (EXCEL) study. IV. Additional perspectives on the tolerability of lovastatin. Am J Med 1991;91(suppl B):25S-30S.